TISIDB

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted.
Domain	PF03487 Interleukin-13
Function	Cytokine (PubMed:8096327, PubMed:8097324). Inhibits inflammatory cytokine production (PubMed:8096327). Synergizes with IL2 in regulating interferon-gamma synthesis (PubMed:8096327). May be critical in regulating inflammatory and immune responses (PubMed:8096327, PubMed:8097324). Positively regulates IL31RA expression in macrophages (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001774 microglial cell activation GO:0001818 negative regulation of cytokine production GO:0001819 positive regulation of cytokine production GO:0001906 cell killing GO:0002065 columnar/cuboidal epithelial cell differentiation GO:0002067 glandular epithelial cell differentiation GO:0002237 response to molecule of bacterial origin GO:0002263 cell activation involved in immune response GO:0002274 myeloid leukocyte activation GO:0002275 myeloid cell activation involved in immune response GO:0002279 mast cell activation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002377 immunoglobulin production GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002444 myeloid leukocyte mediated immunity GO:0002448 mast cell mediated immunity GO:0002637 regulation of immunoglobulin production GO:0002639 positive regulation of immunoglobulin production GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002702 positive regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002705 positive regulation of leukocyte mediated immunity GO:0002886 regulation of myeloid leukocyte mediated immunity GO:0002888 positive regulation of myeloid leukocyte mediated immunity GO:0006816 calcium ion transport GO:0006818 hydrogen transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006887 exocytosis GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0007259 JAK-STAT cascade GO:0007260 tyrosine phosphorylation of STAT protein GO:0009306 protein secretion GO:0009612 response to mechanical stimulus GO:0010155 regulation of proton transport GO:0010522 regulation of calcium ion transport into cytosol GO:0010524 positive regulation of calcium ion transport into cytosol GO:0010959 regulation of metal ion transport GO:0015672 monovalent inorganic cation transport GO:0015992 proton transport GO:0017157 regulation of exocytosis GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0030323 respiratory tube development GO:0030324 lung development GO:0030856 regulation of epithelial cell differentiation GO:0030857 negative regulation of epithelial cell differentiation GO:0030858 positive regulation of epithelial cell differentiation GO:0030888 regulation of B cell proliferation GO:0030890 positive regulation of B cell proliferation GO:0031341 regulation of cell killing GO:0031342 negative regulation of cell killing GO:0032386 regulation of intracellular transport GO:0032388 positive regulation of intracellular transport GO:0032418 lysosome localization GO:0032496 response to lipopolysaccharide GO:0032601 connective tissue growth factor production GO:0032643 regulation of connective tissue growth factor production GO:0032723 positive regulation of connective tissue growth factor production GO:0032844 regulation of homeostatic process GO:0032845 negative regulation of homeostatic process GO:0032846 positive regulation of homeostatic process GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0033002 muscle cell proliferation GO:0033003 regulation of mast cell activation GO:0033005 positive regulation of mast cell activation GO:0033006 regulation of mast cell activation involved in immune response GO:0033008 positive regulation of mast cell activation involved in immune response GO:0033860 regulation of NAD(P)H oxidase activity GO:0033861 negative regulation of NAD(P)H oxidase activity GO:0034762 regulation of transmembrane transport GO:0034764 positive regulation of transmembrane transport GO:0034765 regulation of ion transmembrane transport GO:0034767 positive regulation of ion transmembrane transport GO:0035094 response to nicotine GO:0042100 B cell proliferation GO:0042113 B cell activation GO:0042116 macrophage activation GO:0042505 tyrosine phosphorylation of Stat6 protein GO:0042509 regulation of tyrosine phosphorylation of STAT protein GO:0042525 regulation of tyrosine phosphorylation of Stat6 protein GO:0042526 positive regulation of tyrosine phosphorylation of Stat6 protein GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein GO:0043030 regulation of macrophage activation GO:0043032 positive regulation of macrophage activation GO:0043270 positive regulation of ion transport GO:0043279 response to alkaloid GO:0043299 leukocyte degranulation GO:0043300 regulation of leukocyte degranulation GO:0043302 positive regulation of leukocyte degranulation GO:0043303 mast cell degranulation GO:0043304 regulation of mast cell degranulation GO:0043306 positive regulation of mast cell degranulation GO:0045055 regulated exocytosis GO:0045471 response to ethanol GO:0045576 mast cell activation GO:0045921 positive regulation of exocytosis GO:0046425 regulation of JAK-STAT cascade GO:0046427 positive regulation of JAK-STAT cascade GO:0046651 lymphocyte proliferation GO:0048144 fibroblast proliferation GO:0048145 regulation of fibroblast proliferation GO:0048146 positive regulation of fibroblast proliferation GO:0048659 smooth muscle cell proliferation GO:0048660 regulation of smooth muscle cell proliferation GO:0048661 positive regulation of smooth muscle cell proliferation GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050708 regulation of protein secretion GO:0050714 positive regulation of protein secretion GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation GO:0050864 regulation of B cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050871 positive regulation of B cell activation GO:0051047 positive regulation of secretion GO:0051208 sequestering of calcium ion GO:0051209 release of sequestered calcium ion into cytosol GO:0051222 positive regulation of protein transport GO:0051235 maintenance of location GO:0051238 sequestering of metal ion GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051279 regulation of release of sequestered calcium ion into cytosol GO:0051281 positive regulation of release of sequestered calcium ion into cytosol GO:0051282 regulation of sequestering of calcium ion GO:0051283 negative regulation of sequestering of calcium ion GO:0051341 regulation of oxidoreductase activity GO:0051354 negative regulation of oxidoreductase activity GO:0051480 regulation of cytosolic calcium ion concentration GO:0051640 organelle localization GO:0051656 establishment of organelle localization GO:0051924 regulation of calcium ion transport GO:0051928 positive regulation of calcium ion transport GO:0055074 calcium ion homeostasis GO:0060401 cytosolic calcium ion transport GO:0060402 calcium ion transport into cytosol GO:0060428 lung epithelium development GO:0060433 bronchus development GO:0060479 lung cell differentiation GO:0060480 lung goblet cell differentiation GO:0060481 lobar bronchus epithelium development GO:0060482 lobar bronchus development GO:0060487 lung epithelial cell differentiation GO:0060541 respiratory system development GO:0060627 regulation of vesicle-mediated transport GO:0061140 lung secretory cell differentiation GO:0061141 lung ciliated cell differentiation GO:0070509 calcium ion import GO:0070588 calcium ion transmembrane transport GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0070838 divalent metal ion transport GO:0070997 neuron death GO:0071214 cellular response to abiotic stimulus GO:0071260 cellular response to mechanical stimulus GO:0071496 cellular response to external stimulus GO:0071604 transforming growth factor beta production GO:0071634 regulation of transforming growth factor beta production GO:0071635 negative regulation of transforming growth factor beta production GO:0072343 pancreatic stellate cell proliferation GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:0072577 endothelial cell apoptotic process GO:0090279 regulation of calcium ion import GO:0090280 positive regulation of calcium ion import GO:0097278 complement-dependent cytotoxicity GO:0097305 response to alcohol GO:0097553 calcium ion transmembrane import into cytosol GO:0097696 STAT cascade GO:1901214 regulation of neuron death GO:1901215 negative regulation of neuron death GO:1901246 regulation of lung ciliated cell differentiation GO:1901247 negative regulation of lung ciliated cell differentiation GO:1901249 regulation of lung goblet cell differentiation GO:1901251 positive regulation of lung goblet cell differentiation GO:1902656 calcium ion import into cytosol GO:1903169 regulation of calcium ion transmembrane transport GO:1903305 regulation of regulated secretory pathway GO:1903307 positive regulation of regulated secretory pathway GO:1903532 positive regulation of secretion by cell GO:1903659 regulation of complement-dependent cytotoxicity GO:1903660 negative regulation of complement-dependent cytotoxicity GO:1904019 epithelial cell apoptotic process GO:1904035 regulation of epithelial cell apoptotic process GO:1904036 negative regulation of epithelial cell apoptotic process GO:1904062 regulation of cation transmembrane transport GO:1904064 positive regulation of cation transmembrane transport GO:1904427 positive regulation of calcium ion transmembrane transport GO:1904892 regulation of STAT cascade GO:1904894 positive regulation of STAT cascade GO:1904951 positive regulation of establishment of protein localization GO:2000021 regulation of ion homeostasis GO:2000229 regulation of pancreatic stellate cell proliferation GO:2000231 positive regulation of pancreatic stellate cell proliferation GO:2000351 regulation of endothelial cell apoptotic process GO:2000352 negative regulation of endothelial cell apoptotic process
Molecular Function	GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0005144 interleukin-13 receptor binding
Cellular Component	GO:0009897 external side of plasma membrane GO:0098552 side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04630 Jak-STAT signaling pathway hsa04664 Fc epsilon RI signaling pathway
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-168256: Immune System R-HSA-6783783: Interleukin-10 signaling R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-449147: Signaling by Interleukins

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between IL13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between IL13 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26081225	Esophageal Adenocarcinoma	Inhibit immunity (T cell function)	Because the progression from squamous esophagitis to Barrett's esophagus is accompanied by a transition from a TH1 to TH2 immune response, we hypothesized that the TH2 cytokines IL4/IL13 could contribute to PD-L2 induction. We confirmed that these cytokines can augment PD-L2 expression in esophageal adenocarcinoma cell lines.
19494278	Colon Carcinoma; Prostate Carcinoma	Inhibit immunity	PGDH-mediated antitumor effect was associated with attenuated tumor-induced immune suppression and substantially reduced secretion of immunosuppressive mediators and cytokines such as PGE(2), IL-10, IL-13, and IL-6 by intratumoral CD11b cells. We show also that introduction of 15-PGDH gene in tumor tissue is sufficient to redirect the differentiation of intratumoral CD11b cells from immunosuppressive M2-oriented F4/80(+) tumor-associated macrophages (TAM) into M1-oriented CD11c(+) MHC class II-positive myeloid APCs.
24892809	biliary atresia	Inhibit immunity	The IL-33-dependent proliferative response was mediated by an increase in the number of type 2 innate lymphoid cells (ILC2s), which released high levels of IL-13 that in turn promoted cholangiocyte hyperplasia.
24030977	Glioma	Inhibit immunity (T cell function)	Mice genetically deficient for IL-4Rα exhibited a slower growth of glioma associated with reduced production in the glioma microenvironment of arginase, a marker of myeloid suppressor cells, which is critical for their T-cell inhibitory function. Supporting this result, investigations using bone marrow-derived myeloid cells showed that IL-4Rα mediates IL-13-induced production of arginase.
18490770	Glioblastoma	Inhibit immunity	In addition, direct ex vivo analysis of cytokine expression by TIL from GBM demonstrated significant numbers of IL-4/IL-13 positive cells, cytokines that are integral in the cell-mediated repression of tumor immunity in experimental models.
17016559	colon carcinoma	Inhibit immunity	CD11b+IL-4Ralpha+ cells produced IL-13 and IFN-gamma and integrated the downstream signals of these cytokines to trigger the molecular pathways suppressing antigen-activated CD8+ T lymphocytes. Analogous immunosuppressive circuits were active in CD11b+ cells present within the tumor microenvironment.
16899618	Contralateral	Promote immunity	Cell depletion experiments in tumor-bearing animals indicated that both CD8(+) and CD4(+) T cells contribute to the regression of contralateral tumors through CTL activation in the periphery and cellular infiltration into tumors. In addition, intratumoral treatment into s.c. tumors of mice bearing metastatic lung tumors with IL13-PE38 showed not only the reduction of treated s.c. tumor but also the reduction of lung metastasis. Thus, IL13-PE38 mediates an antitumor effect not only directly but also indirectly by inducing a host CD8(+) T cell immune response.

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of IL13 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of IL13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.922	0.269
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.406	0.356
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.288	0.846
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.147	0.394

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of IL13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL13. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of IL13 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between IL13 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	IL13
Name	interleukin 13
Aliases	IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location	5q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting IL13 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting IL13.

ID	Name	Drug Type	Targets	#Targets
DB05305	Cintredekin Besudotox	Biotech	IL13	1
DB11914	Lebrikizumab	Biotech	IL13	1

Browse IL13